National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) sits in the top decile of US sponsors by registered trial count (#74 of 15,742 sponsors by registered trial count).
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): 490 sponsored US clinical trials, 50 recruiting.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) sponsors 490 registered US clinical trials on ClinicalTrials.gov, 50 of them currently recruiting, and 398 completed. 69 of these trials are in Phase 3-4 (later-stage) and 178 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 25 trials.
Top-decile sponsor footprint
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) ranks in the top decile of sponsors by registered trial count (#74 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
398 of 424 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (93.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
490 total, page 4 of 10
Human Atherosclerotic Plaque Inflammation Imaged Using PDG-PET/CT
NCT00958815
Reduced Carbohydrate Versus Fat in Obese Subjects
NCT00846040
Effects of Recombinant Human Glutamic Acid Decarboxylase on the Progression of Type 1 Diabetes in New Onset Subjects
NCT00529399
Novel Therapy to Preserve Beta Cell Function in New Onset Type 1 Diabetes
NCT00837759
Long-term Follow-up of HALT-C Sustained Virological Responders
NCT00825877
Assessment of the Effects of a DPP-4 Inhibitor (Sitagliptin) Januvia on Immune Function in Healthy Individuals
NCT00813228
Nortriptyline for Idiopathic Gastroparesis
NCT00765895
Pharmacogenomic Response to Thyrotropin-Releasing Hormone Stimulation in Healthy Volunteers: The Influence of a Common Type 2 Deiodinase Genetic Polymorphism on Serum T3
NCT00812149
Improving Health Habits in Impoverished Populations
NCT00569595
Predicting Weight Gain and Weight Loss Associated With Overeating or Fasting
NCT00687115
Primary Prevention of Hypertension in Obese Adolescents
NCT00288158
Experimental Device to Improve Colonoscopy
NCT00719641
High-Dose Ribavirin and Peginterferon to Treat Chronic Hepatitis C Genotype 1
NCT00735969
Cognitive Behavioral Treatment of Depression in ESRD Patients on Dialysis
NCT00618475
TODAY Genetics Study
NCT00722397
Viral Kinetics and Liver Gene Expression in Response to Ribavirin and Peginterferon Therapy of Chronic Hepatitis C
NCT00718172
Antioxidant Treatment of Type 2 Diabetes
NCT00609102
Thyroid Hormones Homeostasis and Energy Metabolism Changes During Stimulation of Endogenously Secreted Bile Acids (BAs)
NCT00706381
Oral Nifedipine to Treat Iron Overload
NCT00712738
A New Method for Determining Gastric Acid Output Using a Wireless Capsule
NCT00702533
Physical Therapy in Women With Interstitial Cystitis
NCT00733603
Effects of Diet Changes on Metabolism
NCT00523627
Hepatitis C Treatment and Atherosclerosis
NCT00659256
Parental Management of Young Children's Diabetes
NCT00847327
Intravenous CTLA4-lg Treatment in Recent Onset Type 1 Diabetes Mellitus
NCT00505375
Computer Based Intervention for Type 2 Diabetes in Youth
NCT00570466
Intraperative Assessment of Renal Perfusion Using Infrared Imaging
NCT00595179
African American Study of Kidney Disease and Hypertension ABPM Pilot Study
NCT00582777
Addressing Emotional and Cognitive Factors in Behavioral Weight Loss Treatment
NCT00533052
Adolescent Self-Management of Type 1 Diabetes: an Intervention (Completed)
NCT00848705
Circuit Training and Motivational Interviewing to Reduce Type 2 Diabetes in Youth
NCT00693511
Effect of Physical Activity on Metabolic Syndrome in Pregnancy & Fetal Outcome
NCT00647595
The Stress-Hormone System in Alcohol-Dependent Subjects
NCT00536146
Effects of Bariatric Surgery on Insulin
NCT00535600
The Effect of Dietary Sitosterol on Blood Sugar and Cholesterol
NCT00531128
Evaluation of Albuminuria HIV-Infected Patients
NCT00524992
Tenofovir Alone Versus Tenofovir With Emtricitabine to Treat Chronic Hepatitis B
NCT00524173
Metabolism and Thyroid Hormone Changes During Exposure to Cold Temperatures
NCT00521729
Effect of Short-Term Beta-Cell Rest in Adolescents and Young Adults With Type 2 Diabetes Mellitus
NCT00445627
Effect of Diet on Vascular Disease in Pre-Menopausal Women
NCT00484861
Randomized Intervention for Children With Vesicoureteral Reflux (RIVUR)
NCT00405704
S-Adenosyl Methionine (SAMe) to Treat Patients With Chronic Hepatitis C
NCT00475176
Effects of N-acetylcysteine on Muscle Fatigue in Hemodialysis
NCT00440869
A Randomized Multicenter Double-Blind CT to Evaluate the Efficacy and Safety of Mycophenolate Mofetil . . .
NCT00451867
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
NCT00419562
Energy Metabolism and Nutrient Absorption in Lean and Obese Individuals
NCT00414063
Physical Therapy Trial for Pelvic Pain
NCT00434343
Botulinum Toxin Injection for the Management of BPH
NCT00451191
Magnetic Resonance Angiography to Diagnose Atherosclerotic Disease
NCT00382564
Parent Supported Weight Reduction in Down Syndrome
NCT01256112
What is open in the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) pipeline
50 recruiting of 490 indexed (10% open); 398 completed (81%).
Phase mix: 69 late (III/IV) vs 178 early (I/II) (early-phase heavy).
Top condition: Obesity (25 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): open-pipeline peers nationwide
Peers matched on 490 registered trials and 10% open enrollment, not the therapeutic-area sidebar.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 490 trials (± recruiting share)
- Beth Israel Deaconess Medical Center · 488 trials · 14% recruiting
- Fred Hutchinson Cancer Center · 483 trials · 12% recruiting
- National Heart, Lung, and Blood Institute (NHLBI) · 501 trials · 12% recruiting
- H. Lee Moffitt Cancer Center and Research Institute · 502 trials · 16% recruiting
Sponsors near 10% open enrollment (± trial volume)
- Mirati Therapeutics · 10% recruiting · 49 trials
- James J. Peters Veterans Affairs Medical Center · 10% recruiting · 39 trials
- California Pacific Medical Center Research Institute · 10% recruiting · 29 trials
- National Institute of Environmental Health Sciences (NIEHS) · 10% recruiting · 145 trials
Related
What to do with this National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) page
490 registered trials is a research-attention snapshot, not an endorsement of National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) or any single study.
- 50 of National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Obesity is the condition National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) pipeline card: 490 registered trials from official public datasets.Report a data error.